Ann: Company Update, page-12

● Management changes to reflect company focus and commitment

Mr Claude Solitario will be appointed Managing Director. Mr Solitario is a founder and major shareholder
of the Company and is suitably qualified to oversee the transition well into the new year. His background,
experience and knowledge of the Company will prove invaluable in ensuring that the Company maintains
and builds on the momentum of ilumenTM and the Company’s FDA program.

Mr Peter Carlisle continues as Lead Non-executive Director. Mr Carlisle has broad insight and an extensive
reach into the US market. With the early success of ilumenTM, we are now well-positioned to take
advantage of Mr Carlisle’s experience and knowledge of the US market.

Ms Melanie Leydin will also continue as a Non-executive Director and joint Company Secretary. Ms
Leydin’s experience in corporate and regulatory matters has been vital during the period of
comprehensive review and we look forward to her continuing involvement.